AbbVie Inc. (ABBV) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 1.52%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value 5.79×; Formula and calculation Operating income ÷ reported interest expense..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 1.52% | Share-based compensation / revenue. Period ending 2026-06-30. $976.00M ÷ $64.39B × 100 ≈ 1.52% |
| Interest coverage · 12 months | 5.79× | Operating income ÷ reported interest expense. $16.87B ÷ $2.92B ≈ 5.79× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | 64.39B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 976.00M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 16.87B USD | Operating Income (Loss) |
| Interest expense · reported / estimated | 2.92B USD | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: Reported. Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $64.39B | $976.00M | $16.87B | $2.92B | (m) | 1.52% | 5.79× | Reported |
| 2026-03-31 | (m) | $62.82B | $989.00M | $15.33B | $2.91B | (m) | 1.57% | 5.27× | Reported |
| 2025-12-31 | (m) | $61.16B | $955.00M | $15.07B | $2.89B | (m) | 1.56% | 5.21× | Reported |
| 2025-09-30 | (m) | $59.64B | $962.00M | $9.04B | $2.88B | (m) | 1.61% | 3.14× | Reported |
| 2025-06-30 | (m) | $58.33B | $934.00M | $10.97B | $2.86B | (m) | 1.60% | 3.83× | Reported |
| 2025-03-31 | (m) | $57.37B | $973.00M | $10.07B | $2.85B | (m) | 1.70% | 3.54× | Reported |
| 2024-12-31 | (m) | $56.33B | $911.00M | $9.14B | $2.81B | (m) | 1.62% | 3.25× | Reported |
| 2024-09-30 | (m) | $55.53B | $872.00M | $13.82B | $2.67B | (m) | 1.57% | 5.18× | Reported |
| 2024-06-30 | (m) | $55.00B | $821.00M | $12.27B | $2.50B | (m) | 1.49% | 4.90× | Reported |
| 2024-03-31 | (m) | $54.40B | $782.00M | $12.79B | $2.33B | (m) | 1.44% | 5.49× | Reported |
| 2023-12-31 | (m) | $54.32B | $747.00M | $12.76B | $2.22B | (m) | 1.38% | 5.74× | Reported |
| 2023-09-30 | (m) | $55.14B | $754.00M | $15.06B | $2.23B | (m) | 1.37% | 6.77× | Reported |
| 2023-06-30 | (m) | $56.02B | $750.00M | $17.39B | $2.23B | (m) | 1.34% | 7.79× | Reported |
| 2023-03-31 | (m) | $56.74B | $678.00M | $16.17B | $2.23B | (m) | 1.19% | 7.23× | Reported |
| 2022-12-31 | (m) | $58.05B | $671.00M | $18.12B | $2.23B | (m) | 1.16% | 8.12× | Reported |
| 2022-09-30 | (m) | $57.82B | $668.00M | $17.69B | $2.24B | (m) | 1.16% | 7.88× | Reported |
| 2022-06-30 | (m) | $57.35B | $677.00M | $17.39B | $2.28B | (m) | 1.18% | 7.63× | Reported |
| 2022-03-31 | (m) | $56.73B | $729.00M | $18.54B | $2.34B | (m) | 1.29% | 7.93× | Reported |
| 2021-12-31 | (m) | $56.20B | $692.00M | $17.92B | $2.42B | (m) | 1.23% | 7.40× | Reported |
| 2021-09-30 | (m) | $55.17B | $699.00M | $16.60B | $2.47B | (m) | 1.27% | 6.72× | Reported |
| 2021-06-30 | (m) | $53.73B | $726.00M | $15.55B | $2.51B | (m) | 1.35% | 6.21× | Reported |
| 2021-03-31 | (m) | $50.20B | $803.00M | $11.86B | $2.52B | (m) | 1.60% | 4.70× | Reported |
| 2020-12-31 | (m) | $45.80B | $753.00M | $11.36B | $2.45B | (m) | 1.64% | 4.63× | Reported |
| 2020-09-30 | (m) | $40.65B | $696.00M | $11.57B | $2.38B | (m) | 1.71% | 4.85× | Reported |
| 2020-06-30 | (m) | $36.23B | $609.00M | $10.93B | $2.23B | (m) | 1.68% | 4.89× | Reported |
| 2020-03-31 | (m) | $34.06B | $460.00M | $13.58B | $1.96B | (m) | 1.35% | 6.93× | Reported |
| 2019-12-31 | (m) | $33.27B | $430.00M | $12.98B | $1.78B | (m) | 1.29% | 7.28× | Reported |
| 2019-09-30 | (m) | $32.87B | $421.00M | $6.59B | $1.60B | (m) | 1.28% | 4.10× | Reported |
| 2019-06-30 | (m) | $32.62B | $421.00M | $7.13B | $1.46B | (m) | 1.29% | 4.87× | Reported |
| 2019-03-31 | (m) | $32.65B | $419.00M | $6.49B | $1.43B | (m) | 1.28% | 4.55× | Reported |
| 2018-12-31 | (m) | $32.75B | $421.00M | $6.38B | $1.35B | (m) | 1.29% | 4.74× | Reported |
| 2018-09-30 | (m) | $32.19B | $428.00M | $10.65B | $1.27B | (m) | 1.33% | 8.41× | Reported |
| 2018-06-30 | (m) | $30.95B | $424.00M | $10.19B | $1.22B | (m) | 1.37% | 8.34× | Reported |
| 2018-03-31 | (m) | $29.61B | $415.00M | $10.09B | $1.19B | (m) | 1.40% | 8.51× | Reported |
| 2017-12-31 | (m) | $28.22B | $365.00M | $9.59B | $1.15B | (m) | 1.29% | 8.34× | Reported |
| 2017-09-30 | (m) | $27.27B | $363.00M | $10.16B | $1.17B | (m) | 1.33% | 8.70× | Reported |
| 2017-06-30 | (m) | $26.71B | $361.00M | $9.81B | $1.14B | (m) | 1.35% | 8.58× | Reported |
| 2017-03-31 | (m) | $26.22B | $356.00M | $9.53B | $1.10B | (m) | 1.36% | 8.62× | Reported |
| 2016-12-31 | (m) | $25.64B | $353.00M | $9.38B | $1.05B | (m) | 1.38% | 8.96× | Reported |
| 2016-09-30 | (m) | $25.24B | $331.00M | $9.14B | $939.00M | (m) | 1.31% | 9.73× | Reported |
| 2016-06-30 | (m) | $24.75B | $317.00M | $8.66B | $875.00M | (m) | 1.28% | 9.90× | Reported |
| 2016-03-31 | (m) | $23.78B | $301.00M | $8.13B | $802.00M | (m) | 1.27% | 10.13× | Reported |
| 2015-12-31 | (m) | $22.86B | $282.00M | $7.54B | $719.00M | (m) | 1.23% | 10.48× | Reported |
| 2015-09-30 | (m) | $21.91B | $272.00M | $5.01B | $650.00M | (m) | 1.24% | 7.71× | Reported |
| 2015-06-30 | (m) | $20.99B | $261.00M | $4.08B | $590.00M | (m) | 1.24% | 6.92× | Reported |
| 2015-03-31 | (m) | $20.44B | $254.00M | $3.75B | $491.00M | (m) | 1.24% | 7.63× | Reported |
| 2014-12-31 | (m) | $19.96B | $241.00M | $3.41B | $429.00M | (m) | 1.21% | 7.95× | Reported |
| 2014-09-30 | (m) | $19.62B | $235.00M | $5.36B | $364.00M | (m) | 1.20% | 14.73× | Reported |
| 2014-06-30 | (m) | $19.26B | $233.00M | $5.77B | $291.00M | (m) | 1.21% | 19.84× | Reported |
| 2014-03-31 | (m) | $19.02B | $231.00M | $5.71B | $297.00M | (m) | 1.21% | 19.23× | Reported |
| 2013-12-31 | (m) | $18.79B | $212.00M | $5.66B | $299.00M | (m) | 1.13% | 18.94× | Reported |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $18.38B | $187.00M | $5.82B | $104.00M | (m) | 1.02% | 55.93× | Reported |
| 2012-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | $17.44B | $163.00M | $3.62B | (m) | (m) | 0.93% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |